These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 34434610)

  • 1. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
    Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
    Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
    Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
    J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
    Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY
    Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma.
    Roders N; Nakid-Cordero C; Raineri F; Fayon M; Abecassis A; Choisy C; Nelson E; Maillard C; Garrick D; Talbot A; Fermand JP; Arnulf B; Bories JC
    Cancer Immunol Res; 2024 Apr; 12(4):478-490. PubMed ID: 38289260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.
    Kang L; Zhang J; Li M; Xu N; Qi W; Tan J; Lou X; Yu Z; Sun J; Wang Z; Fu C; Tang X; Dai H; Chen J; Wu D; Yu L
    Biomark Res; 2020; 8():14. PubMed ID: 32435496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.
    Shi X; Wu Y; Yao X; Du B; Du X
    Front Immunol; 2024; 15():1422478. PubMed ID: 39139556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
    Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
    Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
    Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
    Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.
    Jiang D; Huang H; Qin H; Tang K; Shi X; Zhu T; Gao Y; Zhang Y; Tian X; Fu J; Qu W; Cai W; Xu Y; Wu D; Chu J
    Nat Commun; 2023 Jun; 14(1):3642. PubMed ID: 37339964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
    Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.
    Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa A; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce J; Bogen B; James SE; van den Brink MRM
    Blood; 2024 Jul; 144(2):171-186. PubMed ID: 38579288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.